NanoXplore's U.S. Subsidiary Enters Into a Consent Order With U.S. EPA

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX: GRA and OTCQX: NNXPF) announces that on August 13, 2021, its U.S. subsidiary RMC Advanced Technologies Inc. entered into a consent order with the U.S. Environmental Protection Agency (" EPA ") under the Toxic Substances Control Act (TSCA) (the " Consent Order "), which Consent Order allows for the commercial use of its GrapheneBlack TM as an additive for thermoplastics, thermosets and rubbers, with no annual volume limitation.

Soroush Nazarpour, President and Chief Executive Officer of NanoXplore, commented:

"This long-awaited news constitutes a significant milestone for NanoXplore, as it opens the GrapheneBlack TM market in the U.S. It marks a historic year for us: Eleven years after graphene winning the Nobel Prize, NanoXplore's graphene reaches regulatory approval for industrial volumes in the U.S."

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Corporation provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

For more information, please contact:

Soroush Nazarpour
President and Chief Executive Officer
NanoXplore Inc.
(514) 935-1377
info@NanoXplore.ca


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Longeveron Granted Small or Medium-sized Enterprise  Status by the European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...

Interactive Chart

Latest Press Releases

Related News